



Consonus Healthcare consonushealth.com

Plan provided by Consonus Pharmacy

Road to Recovery: Update












Information current as of 3.26.2021



State Update: Ready to Activate!








Current State

What we Know.....

- Keep going!
- Drop in case rate
- Reopening plan
- 5,000 Residents / 8,000 Staff left to vaccinate
- Consonus has 500 new recipients/week
- Pfizer is still available
- J&J Nevada
- Moderna still pending







Current Consonus Stats Phase 2 (Beta):

Date of Last Clinic

3.19.2021

Date of Beta

3.1.2021













Agreements Received

85%

Facilities Activated

31

Phase 2 Doses

559





Policy Considerations: Community Based Care







Step by Step Activation:









Activate:



Activate

- Agreement
- Identify FC
- Identify Vaccinator
- FC Website Training
- Vaccinator Training
- Life Enrichment List
- Standing Orders
- Physician Order



Order



Receive



Vaccinate





Thank you for your interest in participating in the COVID-19 Vaccine Continuity Program through Consonus Pharmacy. To reach activation status, please complete the following steps.

Step 1: Vaccination Agreement

 Return the signed vaccination agreement that was provided to you through DocuSign. If you participated in phase 1 clinics with Consonus, your agreement is already in place. If you are new to Consonus' vaccine program and did not receive your Vaccination Agreement, please contact your nurse or pharmacist consultant.

Step 2: Identify Facility Coordinator

 The Administrator, DNS /HWD or other leadership personnel within the facility should take on the Facility Coordinator (FC) role. The FC will be accountable and attest that requirements have been achieved for the Continuity Program at the facility. This person is responsible for ordering and securing the VaccPack as well as keeping the patient roster up to date in the Vaccine Administration Software (VAS). The FC will also manage an on call list to minimize waste of the vaccine at the facility site. Note, on call recipients must be within your local jurisdiction's current guidelines for COVID-19 vaccine

Step 3: Identify Facility Vaccinator

 Secure healthcare provider(s) to administer vaccinations. Reconstitution may also be required, if utilizing the Pfizer product. Many states have expanded who can administer the COVID-19 vaccine during this national emergency. Please check your current state requirements on who can vaccinate.

Step 4: Facility Standing Orders

 Some states have standing orders for each vaccine product that allow healthcare professionals to administer the vaccine without individual patient orders. If your state does not have a standing order, the CDC has a template that may be utilized.

Step 5: Vaccine Allergic Reaction Box (VARB) Physician Order

 Each facility must purchase a VARB from the pharmacy to have onsite during vaccinations. Per the CDC guidance to administer the COVID vaccine, you must have 3 epinephrine auto injectors and an antihistamine (i.e. diphenhydramine). A link to a sample order is attached. Please have a prescriber sign and send back to pharmacy.

Step 6: Facility Coordinator and Vaccine Administrator Training

 Have VAS users view the following videos. Note, there have been several updates to the VAS since phase 1. For this reason, regardless if you have participated in phase 1 clinics, you are required to watch the appropriate trainings for your role.

Facility Coordinator:

- "Facility Coordinator VAS Training Video"
 "Vaccine Administrator VAS Training"

 - "Vaccine Prep and Administration" (product specific)

Step 7: Activation Confirmation or Training Access

 Once you have completed all steps, please fill out the "Ready to Activate" form to validate all steps have been completed. A vaccine coordinator will then contact you with your first order date





Ready Set GO! Activation Check List

Vaccination Agreement	
Identify Facility Coordinator	
Identify Facility Vaccinator	
Facility Standing Order	Check state requirements Washington State Standing Orders CDC Standing Order Pfizer CDC Standing Order Moderna
Vaccine Allergic Reaction Box Order	WA Pharmacy Customer OR Pharmacy Customer CA Pharmacy Customer NV Pharmacy Customer
Facility Coordinator Training	Facility Coordinator VAS Training Vid Review Training Guide
Vaccinator Training	Vaccine Administrator VAS Training Vaccine Prep and Administration (product specific) Review Training Guide
Fill Out "Ready to Activate" Form	Ready to Activate

Please note, Consonus vaccine supply may vary based on state and federal allocation. Fluctuating vaccine supply may delay facilities preferred vaccination schedule.



Activation

Check List:





Step1: Vaccination Agreement



- Phase 1 participants Agreement already in place.
- Parent company agreements may be in place.
- If you are unsure if you have an agreement or need one, please reach out to you consultant pharmacist or nurse.









Step 2: Identify Facility Coordinator

Who:

Leadership

Responsibilities:

- Attest to requirements
- Maintain roster
- Order vaccine
- Coordinate delivery
- Maintain security
- Report end of clinic inventory
- Maintain life enrichment list









Step 3: Identify Facility Vaccinator



Responsibilities:

- Clinical screening
- Vaccination
- Documentation in VAS
- CDC vaccination card
- Post vaccine monitoring







Step 4: Clinical Standing Orders for Administration



Moderna COVID-19 Vaccine

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older



Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Purpose

 To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

>> Polic

 Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

>> Procedure

02/11/2021 C\$321571-H

Assess persons 18 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- No complete 2-dose COVID-19 vaccination history, regardless of brand. If 2 doses of a same-brand or mixedbrand series have been administered, no additional doses are recommended.
- If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, a second dose of the same brand should be administered.
- If the vaccine product previously given cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
- This vaccine is administered in a 2-dose series. Separate doses by at least 28 days, preferably within 6 weeks."
- Moderna COVID-19 Vaccine should not be administered at the same time as other vaccines. Separate Moderna COVID-19 Vaccine from other vaccines by 14 days before or after the administration of Moderna COVID-19 Vaccine.
- Moderna COVID-19 Vaccine should be deferred for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment

- If the recipient has a history of dermal filler use, advise them to contact their healthcare provider for evaluation if they develop swelling at or near the dermal filler site following vaccination.
- Screen for contraindications and precautions.

o Contraindication

- » Severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of either mRNA COVID-19 vaccine.
- » Immediate allergic reaction* of any severity to a previous dose or component of an mRNA COVID-19 vaccine (including polyethylene glycol [PEG]). See Table 1 of vaccine components on page 3.
- » Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG).

o Precautions

- » History of an immediate allergic reaction to any other vaccine or therapies [excluding subcutaneous immunotherapy of allergies, i.e. "allergy shots"] not related to a component of mRNA COVID-19 vaccines or polysorbate).
- » Moderate to severe acute illness.
- Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.
- Prepare to administer the vaccine.

Sex and Weight of Patient	Needle Gauge	Needle Length	Injection Site†
Female or male fewer than 130 lbs	22-25	% ⁵ −1"	Deltoid muscle of arm
Female or male 130–152 lbs	22-25	1"	Deltoid muscle of arm
Female 152–200 lbs	22-25	1-11/2"	Deltoid muscle of arm
Male 153–260 lbs	22-25	1-11/2"	Deltoid muscle of arm
Female 200+ lbs	22-25	11/2"	Deltoid muscle of arm
Male 260+ lbs	22-25	11/2"	Deltoid muscle of arm

"Administer the second dose as close to the recommended interval (28 days) as possible. If the second dose is not administered within 6 weeks of the first dose, the series does not need to be restarted. Doses inadvertently administered less than 28 days apart do not need to be repeated.

*However, mRNA COVID-19 and other vaccines may be administrated within a therete period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration (e.g., tetanus troud-containing vaccination as part of vound management, rabbies vaccination for poix-exposure prophylaxis, measies or hepatitis A vaccination during an outbreakl or to avoid barriers or delays to mRNA COVID-19 vaccination.

"For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angiodetema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

⁷Alternatively, the anterolateral thigh also can be used. ⁵Some experts recommend a 5/8-inch needle for men and women who weigh less 130 pounds. If used, skin must be stretched tightly ide net bunch subcutaneous tissuel.



Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine to Persons 16 Years of Age and Older



Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Purpose

 To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

>> Policy

 Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

>> Procedure

- Assess persons 16 years of age and older for vaccination with Pfizer-BioNTech COVID-19 Vaccine based on the following criteria:
- No complete 2-dose COVID-19 vaccination history, regardless of brand. If 2 doses of a same-brand or mixed-brand series have been administered, no additional doses are recommended.
- If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, the second dose of the same brand should be administered.
- If the vaccine product previously given cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
- This vaccine is administered in a 2-dose series.
 Separate doses by at least 28 days, preferably within 6 weeks *
- Pfizer-BioNTech COVID-19 Vaccine should not be administered at the same time as other vaccines. Separate Pfizer-BioNTech COVID-19 Vaccine from other vaccines by 14 days before or after the administration of Pfizer-BioNTech COVID-19 Vaccine.¹

- Pfizer-BioNTech COVID-19 Vaccine should be deferred for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment.
- No complete 2-dose COVID-19 vaccination history,
 Screen for contraindications and precautions.
 - Contraindications:
 - » Severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of either mRNA COVID-19 vaccine.
 - » Immediate allergic reaction* of any severity to a previous dose or component of an mRNA COVID-19 vaccine (including polyethylene glycol [PEG]). See Table 1 of vaccine components on page 3.
 - Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG).

o Precautions:

- » History of an immediate allergic reaction to any other vaccine or therapies (excluding subcutaneous immunotherapy of allergies, i.e. "allergy shots") not related to a component of mRNA COVID-19 vaccines or polysorbate).
- » Moderate to severe acute illness.
- Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.
- Prepare to administer the vaccine.

Sex and Weight of Patient	Needle Gauge	Needle Length	Injection Site†
Female or male fewer than 130 lbs	22-25	%9-1"	Deltoid muscle of arm
Female or male 130–152 lbs	22-25	1"	Deltoid muscle of arm
Female 152–200 lbs	22-25	1-11/2"	Deltoid muscle of arm
Male 153–260 lbs	22-25	1-11/2"	Deltoid muscle of arm
Female 200+ lbs	22-25	11/2"	Deltoid muscle of arm
Male 260+ lbs	22-25	11/2"	Deltoid muscle of arm

*Administer the second dose as close as possible to the recommended interval (21 days). If the second dose is not administered within 6 weeks of the first dose, the series does not need to be restarted. Second doses inadvertently administered less than 21 days apart do not need to be repeated.

*However, mBMA COVID-19 and other vaccines may be administred within a shorter period in situations where the honefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration (e.g., tetanus toxid-containing vaccination as part of wound management, tables vaccination for post-exposure prophylaxis, measless or hepatists. A vaccination during an outbreask of or to avoid barrier or delays to mBMA COVID-19 vaccination. "For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylausis that occur within 4 hours following exposure to a vaccine or medication.

[†]Alternatively, the anterolateral thigh also can be used. [§]Some experts recommend a 5/8-inch needle for men and women who weigh less 130 pounds. If used, skin must be stretched tightly ido not bunch subcutaneous tissue).

2/11/2021 CS321570-H



Consonus Healthcare consonushealth.com

Plan provided by Consonus Pharmacy





Step 5: Requirement to Give Vaccine



- Epinephrine in prefilled autoinjector
- Antihistamine (Benadryl)
- Access to call 911



First Aid Kit



Stethoscope



Blood pressure cuff



Timing devise for pulse



Oxygen



Pulse Oximeter





Step 5: Vaccine Allergic Reaction Box (VARB)



- Epinephrine in prefilled autoinjector (3)
- Antihistamine (diphenhydramine)












Step 6: Training



Required Training:

- Facility Coordinator Vaccine Administration Software Video
- Knowledge of current jurisdiction for vaccinating





Required Training:

- "Vaccine Administrator VAS Training" Video
- "Vaccine Prep and Administration" Video
- Knowledge of current jurisdiction for vaccinating







Step 7: Ready to Activate?

- Fill out "Ready to Activate" form
- After completion of activation steps
- Attest that all steps have been achieved
- Consonus to verify
- Confirmation email sent to facility coordinator

Please complete and submit the following form to indicate readiness for activation with the Consonus Vaccine After submission of this form, Consonus will contact the Facility Coordinator named below to coordinate activation and notify you of the earliest date you can place a vaccine order. Please note, Consonus vaccine supply may vary based on state and federal allocation. Fluctuating vaccine supply may delay facilities' preferred vaccination schedule. * Required 1. Facility Name 5 Enter your answer 2. Facility Coordinator Name * Enter your answer 3. Facility Coordinator Email Address * Enter your answer 5. All of the following items have been completed: 1 Signed Vaccine Continuity Program agreement sent to Consonus Signed prescription for epinephrine under the name of the facility sent to Consonus Standing order to administer vaccine obtained 6. The Facility Coordinator has reviewed all of the following training materials related to the vaccine ordering process and Vaccine Administration Software (VAS): * Training materials can be accessed here: https://confluence.marquiscompanies.com/pages/viewpage.action?pageId=54887559 Watched Facility Coordinator VAS training video Watched Vaccine Administrator VAS training video Reviewed VAS guide Reviewed Consonus Pharmacy Vaccine Delivery Schedule Submit Never give out your password. Report abuse

Ready to Activate Form



Moving from Clinics to Continuity:




Activate

- Agreement
- Identify FC
- Identify Vaccinator
- FC Website Training
- Vaccinator Training
- Physician Order
- Standing Orders
- Life Enrichment List



Order

- Maintain patient's roster
- e-Consent
- EUA
- 2 Days in Advance
- Rx Verification



Receive



Vaccinate



Ordering Key Points:



Activation completed and confirmed



Roster uploaded prior to ordering



Order 2 days in Advance



Vaccinator Scheduled



Shipped Monday – Friday Only

 Your clinics should be scheduled Tuesday - Saturday




Know State Phase Criteria



Ordering the VaccPack:










Ordering the VaccPack:









Ordering the VaccPack:

Roster Verified by Consonus











Moving from Clinics to Continuity:




Activate

- Agreement
- Identify FC
- Identify Vaccinator
- FC Website Training
- Vaccinator Training
- Physician Order
- Standing Orders
- Life Enrichment List



Order

- Maintain patient's roster
- e-Consent
- EUA
- 2 Days in Advance
- Rx Verification



Receive

- Consistent Location
- Secure
- Do Not Open



Vaccinate



Introducing the VaccPack:








- Vaccine
- Diluent 0.9% NS Vial
- Vaccine Dilution Instructions
- Syringe(s)
- Alcohol Swabs
- CDC Cards

Band-Aides



Recieving:



Routine Delivery:

- Use within 24 hours of receipt
- Product is to stay in pharmacy packaging until ready to vaccinate.





Moving from Clinics to Continuity:



Activate

- Agreement
- Identify FC
- Identify Vaccinator
- FC Website Training
- Vaccinator Training
- Physician Order
- Standing Orders
- Life Enrichment List



Order

- Maintain patient's roster
- e-Consent
- EUA
- 2 Days in Advance
- Rx Verification



Receive

- Central Location
- Secure
- Do Not Open



- Vaccinate
- Allergic Reaction Box
- Vaccination Kit
- Screen
- Monitor
- Inventory Report





Screening Protocols Remain in Place



Pre-Vaccination Form for Pfizer-BioNTech COVID-19 Vaccine



Information for Healthcare Professionals about the Pre-Vaccination Form for Pfizer-BioNTech COVID-19 Vaccine.

For additional information on COVID-19 vaccina

https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ dinical-considerations.html

For additional information on ACIP general recommendations, see:

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/Index.html

re you feeling sick today?

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (e.g., upper respiratory infactions, diarnhan) are NOT contraindications to vaccination. Do not withhold vaccination if a parson is taking antibiotics. Vaccination of persons with current SARS-CoV-2 infaction should be deferred until the person has recovered from acute illness and they can discontinue isolation. While there is no minimum interval between infaction and vaccination, current evidence suggests reinfaction is uncommon in the 90 days after initial infaction. Persons with documental acute SARS-CoV-2 infaction in the preceding 90 days may delay vaccination until near the end of this period, if desired.

Have you ever received a dose of COVID-19 vaccine? Two doses of the same COVID-19 vaccine product are recommended. Check medical records, immunization information systems, and vaccination record cards to help determine the initial product received. Those who received a trial vaccine should consult with the trial sponsors to determine if it is feasible to receive additional doses.

Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something? For example, a reaction for which you were treated with epinephrine or EpiPen*, or for which you had to go to the hospital? Allergic reactions, including severe allergic reactions, NOT

Allargic reactions, including severe allergic reactions, NOT related to vaccines or injectable therapies (e.g., food, pet, venom, environmental, or later allergies; oral medications) are NOT a contraindication or precaution to vaccination with currently authorized COMD-19 vaccina. HOWEVER, individuals who have had severe allergic reactions to something, regardless of cause, should be observed for 30 minutes after vaccination. All other persons should be observed for 15 minutes.

Was the severe allergic reaction after receiving a COVID-19 vaccine?

History of severe allergic reaction (e.g., anaphylaxis) to a pravious dose or component of the COVID-19 vaccine product being offered is a contraindication to that COVID-19 vaccine.

Was the severe allergic reaction after receiving another vaccine or another injectable medication?

A history of mild allergic reaction to a vaccine or injectable therapy is not a precaution to vaccination. History of severe allergic reaction (e.g., anaphylaxis) to another vaccine or a component of another vaccine OR anaphylactic reaction to any other injectable madication is a precaution to currently authorized COVID-19 vaccine. Vaccine may be given, but counsel patients about unknown risks of developing a severe allergic reaction and balance these risks against the benefits of vaccination. These individuals should be observed for 30 minutes after vaccination.

Do you have a bleeding disorder or are you taking a blood thinner?

COMD-19 vaccine may be given to these patients, if a physician familiar with the patient's bleading risk determines that the vaccine can be administered intramuscularly with reasonable safety, ACIP recommends the following technique for intramuscular vaccination in patients with bleading disorders or taking blood thinners: a fine-gauge needle [23-gauge or smaller calibar) should be used for the vaccination, followed by firm pressure on the site, without nabling for at least 2 minutes.

Have you received passive antibody therapy as treatment for COVID-19?

Based on the estimated half-life of monoclonal antibodies or convalencem plasma as part of COMD-19 treatment, as well as evidence suggesting that reinfection is uncommon in the 90 days after initial infection, vecalization should be adecrated for at least 90 days, as a precounionary measure until additional information becomes available, to avoid interference of the antibody treatment with vectoria-induced immune responses.

» Considerations

Immunocompromise is not a contraind cation to current COVID-19 vactive, including those with cancer, leukemia, HIV/AIDS and other immune system problems or taking medication that affects their immune systems. However, patients should be informed that the vaccine might be less effective than in someone who is immunocompetent.

Pregnancy is not a contraindication to current COVID-19 vaccine. While there are currently no available data on the safety of COVID-19 vaccines in pregnant people, studies and results are expected soon. Pregnant people may choose to get vaccinized. Observational data demonstrate that while the absolute risk is low, pregnant people with COVID-19 have an increased risk of several liness.

Lactation is not a contraindication to current COVID-19 vacidns, Lactating people may choose to be vaccinated. There is no data available for lactating people on the effects of mRNA vaccines.

Pre-Vaccination Form for Pfizer-BioNTech COVID-19 Vaccine



For vaccine recipients:

The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine today. If you answer "yes" to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions may be asked. If a question is not clear, please ask your builds not seem that the covid of the

Patient Name	
Age	

	Yes	No	Do:
Are you feeling sick today?			
Have you ever received a dose of COVID-19 vaccine?			
If yes, which vaccine product?			
Pfizer			
☐ Another product	-		
3. Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something?			Т
For example, a reaction for which you were treated with epinephrine or EpiPen®,			
or for which you had to go to the hospital?			-
Was the severe allergic reaction after receiving a COVID-19 vaccine?			
Was the severe allergic reaction after receiving another vaccine or			
another injectable medication?			\perp
4. Do you have a bleeding disorder or are you taking a blood thinner?			
Have you received passive antibody therapy as treatment for COVID-19?			
n completed by Date			
n reviewed by Date			
ted with appreciation from the Immunication Action Coalition (IAC) acreening checklists			




2



Report Inventory:










Report Inventory:










COVID Vaccines Authorized for Use:



- Pfizer
- Moderna
- Janssen

The best vaccine is the one readily available to you!











Storage and Handling:

		moderna	Pfizer	Janssen PHARMACEUTICAL COMPANIES OF Gohnson-Gohnson
† † †	Age	18 yo	16 yo	18 yo
	Between doses	28 days	21 Days	Single Dose
	Room Temp (unopened vials)	12 hours	2 hours	12 hours
	In use vials	6 hours after puncture	6 hours after dilution	2 hours-rm temp 6 hours - refrigerator






Product Comparison:

		moderna	Pfizer	Janssen PHARMACEUTICAL COMPANIES OF Johnson-Johnson
0	Dilution	None, ready to use	Dilute with saline	None, ready to use
5	Doses/Vial	10	6	5
	Dose	0.5 ml lM	0.3ml IM	0.5 ml IM





#GetVaccinated:








Pharmacy Updates:

Pharmacy lowering infection control policy to level 2! April 1, 2021



Going back to pre-COVID delivery methods





Pharmacy Updates:






















































Best Case Schedule:







The Goal:



Maintain ≥ 75% full vaccination protection within LTC facilities.



Decrease community positivity rates.



Reopen! Bring community and families back together.





Maximize product, minimizing waste





Get Started?






Order VaccPack!





Questions?



- Check our website for the latest information
- This presentation will be sent out and available on the website Monday
- FAQ Friday answering your commonly asked questions
- When we have information, you will hear from us



